STEPAN CO SCL revenue by segment, product and geography
In its fiscal year ending 2025-12-31, STEPAN CO reported revenue across 3 business segments; the largest, Surfactants, was $1.67B, 71.4% of the filed sum (+8.7% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Surfactants$1.67B71.4%+8.7% yoy
- Polymers$584M25.1%-0.1% yoy
- Specialty Products$81.7M3.5%+29.1% yoy
Members sum to the consolidated $2.33B for this period.
- North America$1.34Bshare n/a+7.9% yoy
- United States$1.3Bshare n/a+8.1% yoy
- Europe$543Mshare n/a+4.9% yoy
- Latin America$358Mshare n/a+11.6% yoy
- France$211Mshare n/a+22.1% yoy
- All Other Countries$182Mshare n/a+0.2% yoy
- United Kingdom$170Mshare n/a-2.9% yoy
- Mexico$164Mshare n/a+9.0% yoy
- +3 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Surfactants$454M75.1%+5.4% yoy
- Polymers$130M21.5%-11.0% yoy
- Specialty Products$20.8M3.4%+23.8% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.